AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21440942
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 4 mg intravitreal triamcinolone
Trial: 19004201
Drug: Yiweikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiweikang Capsule
Trial: 19004201
Drug: Wenweishu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenweishu Capsule
Trial: 9291901
Drug: Constant-rate infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant-rate infusion
Trial: 3525369
Drug: Sclerotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy plus oral propranolol (dose sufficient to reduce resting pulse rate by 25%)
Trial: 31294749
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg/kg every 3 weeks) after 3 doses of 8 Gy stereotactic body radiotherapy
Trial: 31294749
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg/kg every 3 weeks) alone (control arm)
Trial: 23434449
Drug: Penehyclidine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine hydrochloride (0.05 mg/kg IV 10 minutes before cardiopulmonary bypass)
Trial: 19876674
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) with varied administration of exposure
Trial: 9207282
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg, 3 mL intramuscular injection)
Trial: 9207282
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mL saline, intramuscular injection)
Trial: 8272262
Drug: GM-1 ganglioside,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-1 ganglioside, administered intravenously at a dose of 100 mg, 6 days a week for 2 months
Trial: 3619096
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus 1 ml normal saline (Group 1)
Trial: 3619096
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus 0.2 mg epinephrine (Group 3)
Trial: 3619096
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus 0.3 mg epinephrine (Group 4)
Trial: 3619096
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus 0.4 mg epinephrine (Group 5)
Trial: 3619096
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus 0.5 mg epinephrine (Group 6)
Trial: 19117033
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (3 g/day) plus vitamin D (1 mg/day) (Group A, n=49)
Trial: 19117033
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (Group C, n=50)
Trial: 17522475
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) low dose (50 mg/week)
Trial: 17522475
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) medium dose (100 mg/week)
Trial: 17522475
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) high dose (200 mg/week)
Trial: 12193356
Drug: Thrombolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis treatment in a clinical trial
Trial: 12193356
Drug: Thrombolysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis treatment if shown effective
Trial: 7973772
Drug: Cisplatin/5-fluorouracil/leucovorin (PFL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/5-fluorouracil/leucovorin (PFL) combination
Trial: 7973772
Drug: Vinorelbine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine at 20 mg/m2/d
Trial: 7973772
Drug: Vinorelbine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine at 25 mg/m2/d
Trial: 2700878
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (O.C.)
Trial: 21150602
Drug: Isolated limb
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated limb infusion (ILI) with melphalan and actinimycin D
Trial: 19567091
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Trial: 19567091
Drug: 7 ml
RxNorm normalized name: ethanol 7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Trial: 19567091
Drug: 6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Trial: 19567091
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Trial: 16389160
Drug: Quinapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril plus Losartan (20 mg/day + 100 mg/day)
Trial: 11070965
Drug: Preemptive intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive intravenous morphine (0.15 mg.kg‐1)
Trial: 11070965
Drug: Preemptive epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive epidural morphine (75 micrograms.kg‐1)
Trial: 11070965
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous saline)
Trial: 9061114
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg of vecuronium administered 5 minutes prior to inflation of a pneumatic tourniquet (Group I)
Trial: 9061114
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg of vecuronium administered after inflation of the tourniquet (Group II)
Trial: 9061114
Drug: Neostigmine 30‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 30‐40 micrograms/kg i.v. administered to all subjects in both groups
Trial: 8112641
Drug: Closure including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Closure including subcutaneous retention sutures
Trial: 21349756
Drug: Pédimed(®) cream
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pédimed(®) cream applied twice daily for 4 weeks
Trial: 21349756
Drug: Pédimed(®) cream
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pédimed(®) cream
Trial: 15932664
Drug: Nadroparin (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (0.075 ml/10 kg)
Trial: 12172535
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G (2.4 million units, intramuscular injection)
Trial: 10682964
Drug: Brinzolamide 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 1.0% twice daily
Trial: 10682964
Drug: Brinzolamide 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 1.0% three times daily
Trial: 9744373
Drug: Brinzolamide 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 1.0% (twice daily)
Trial: 9744373
Drug: Brinzolamide 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 1.0% (three times daily)
Trial: 7544184
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (before immunotherapy)
Trial: 869668
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride (various doses)
Trial: 26302034
Drug: Low-fat yoghurt
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat yoghurt supplemented with 80 mg d(‐1) of rooster comb extract (RCE)
Trial: 16647404
Drug: Pamidronate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate therapy
Trial: 10824468
Drug: Epsilon aminocaproic
RxNorm normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon aminocaproic acid (100 mg/kg body wt) intravenously slowly soon after anaesthetic induction, followed by 100 mg/kg in the cardiopulmonary bypass pump and 100 mg/kg after weaning from bypass over a period of 3 h
Trial: 9035702
Drug: Once-daily treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily treatment of Tazarotene
Trial: 1627203
Drug: Sertaconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole 1% cream applied twice a day for 4 weeks
Trial: 1627203
Drug: Sertaconazole 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertaconazole 2% cream applied twice a day for 4 weeks
Trial: 6148959
Drug: Bisoprolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 40 mg
Trial: 24925722
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibitors (mostly but not entirely)
Trial: 18039351
Drug: BAY 79‐4980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 79‐4980 (13 or 22 mg kg(‐1) pegylated liposomes)
Trial: 17665483
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneously every other week for 24 weeks
Trial: 7555033
Drug: 1 capsule
RxNorm normalized name: Cebocap 1 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule twice daily (A)
Trial: 7555033
Drug: 2 capsules
RxNorm normalized name: Xymogen Berberine With Insea2 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules in the morning and 1 in the evening (B)
Trial: 7555033
Drug: 2 capsules
RxNorm normalized name: Xymogen Berberine With Insea2 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules twice daily (C)
Trial: 2258450
Drug: Amoxapine 400
RxNorm normalized name: Amoxapine
DrugBank: Amoxapine (DB00543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxapine 400 mg
Trial: 2258450
Drug: Amitriptyline 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 300 mg
Trial: 7008475
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (LDH)
Trial: 31900193
Drug: Lottery prizes
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lottery prizes conditional on high adherence measured by a medication event management system (MEMS) cap (T2, n=110)
Trial: 30539411
Drug: IMR-cCTA (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMR-cCTA (80 kV; automated-mAs; 60 mL of CM, 350 mgL/mL)
Trial: 24350624
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with totally extraperitoneal endoscopic mesh placement
Trial: 19920416
Drug: Mepivacaine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 400 mg diluted in 20 mL
Trial: 19920416
Drug: Mepivacaine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 400 mg diluted in 30 mL
Trial: 19920416
Drug: Mepivacaine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine 400 mg diluted in 40 mL
Trial: 14756642
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects of treatment
Trial: 11708314
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (10 g protein, 7 g carbohydrate, 3.3 g fat, and one-third of RDA of vitamins and minerals) ingested immediately after exercise.
Trial: 11708314
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) did not ingest the protein supplement.
Trial: 9514139
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg of AA, daily for the first week of life
Trial: 3406600
Drug: Drugs or
RxNorm normalized name: herbal drugs ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs or relaxation therapy
Trial: 31129371
Drug: Intensive Telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Telephone Counseling (ITC; eight proactive sessions/eight weeks of nicotine patches, plus discussion of the LCS results)
Trial: 31129371
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care (UC; three proactive telephone counseling sessions/two weeks of nicotine patches)
Trial: 26780271
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) adjunct to scaling and root planing (SRP)
Trial: 26780271
Drug: Conventional non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non-surgical periodontal therapy (NSPT)
Trial: 24996197
Drug: Brivanib 800
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib 800 mg orally once-daily
Trial: 22406155
Drug: Anti-TB drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TB drug treatment
Trial: 19783386
Drug: Modafinil (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200, 400, or 600 mg)
Trial: 17645384
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy plus cardiac rehabilitation
Trial: 9051540
Drug: IV ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ondansetron 4 mg and saline
Trial: 9051540
Drug: IV ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ondansetron 4 mg followed by IV dexamethasone 20 mg
Trial: 3002987
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B polysaccharide and OMV vaccine
Trial: 3403868
Drug: Theolan Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolan Suspension (administered every 12 hours)
Trial: 3403868
Drug: Aminophylline solution
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline solution (administered every 8 hours)
Trial: 3403868
Drug: Theolan Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolan Suspension
Trial: 3403868
Drug: Aminophylline solution
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline solution
Trial: 31915170
Drug: Personalised intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalised intervention including interactive responses and medication and follow-up reminders, in addition to usual care and general educational messages.
Trial: 28011243
Drug: Drug-Eluting Balloon
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Balloon (DEB)
Trial: 26790201
Drug: Interactive dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive dynamic scalp acupuncture therapy
Trial: 26790201
Drug: Traditional scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional scalp acupuncture therapy
Trial: 21569309
Drug: Sertraline (titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (titration up to the minimum vs maximum of the recommended dose range)
Trial: 21569309
Drug: Sertraline (staying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (staying on sertraline)
Trial: 21569309
Drug: Sertraline (augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (augmentation with mirtazapine)
Trial: 21569309
Drug: Mirtazapine (switching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (switching from sertraline to mirtazapine)
Trial: 15605345
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy (PT) care
Trial: 11370405
Drug: Drug information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug information from the pharmaceutical industry
Trial: 24848990
Drug: Ibuprofen sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen sodium 400 mg
Trial: 24848990
Drug: Ibuprofen-poloxamer 400
RxNorm normalized name: Poloxamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-poloxamer 400 mg
Trial: 24128134
Drug: Sirolimus (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (initiated at 2 mg/d, adjusted to 6 to 8 ng/mL)
Trial: 21403463
Drug: DTwP‐HBV+Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP‐HBV+Hib vaccine (SIIL)
Trial: 21403463
Drug: TritanrixHB+Hiberix vaccine
RxNorm normalized name: Hiberix
DrugBank: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (DB10990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TritanrixHB+Hiberix vaccine (GSK)
Trial: 21403463
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose for both SIIL and GSK groups
Trial: 10879992
Drug: Cetirizine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine treatment for 6 weeks
Trial: 10879992
Drug: Cetirizine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine treatment for 1 week
Trial: 3535490
Drug: Oral milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral milrinone therapy (10 +/- 1 weeks)
Trial: 3535490
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone after withdrawal of oral drug for 24 hours
Trial: 3535490
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of oral milrinone
Trial: 31338575
Drug: Antiadhesive agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiadhesive agent
Trial: 31338575
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiadhesive agent)
Trial: 24641978
Drug: Acute heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute heroin administration
Trial: 22243563
Drug: THC (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (0.025 mg/kg)
Trial: 16315875
Drug: Cimetidine administration
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine administration during chemotherapy
Trial: 16315875
Drug: Non-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-administration of cimetidine during chemotherapy
Trial: 11782685
Drug: Cefaclor AF
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor AF (500 mg BID for 10 days)
Trial: 11782685
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (250 mg BID for 10 days)
Trial: 2563327
Drug: Home-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based treatment with massed exposure
Trial: 2563327
Drug: Home-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based treatment with spaced exposure
Trial: 2563327
Drug: Home-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based treatment with self-controlled exposure
Trial: 2563327
Drug: Home-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based treatment with therapist-controlled exposure
Trial: 31833974
Drug: Anti-HER2 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-HER2 therapy
Trial: 27682868
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives (£15 for each LAI medication)
Trial: 9607059
Drug: Live human
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live human rotavirus vaccine 89-12 (10^5 p.f.u. dose-1)